Eisai Inc. Prep Session, March 1, 2007 Elena Arvanitis Site visit, March 2, 2007 Seminar topic Investing in the Rx Industry – Mixing Medicine with Business

HISTORY PMSIG Prep session 03/01/07 Eisai Co Ltd founded in Japan in 1941 as Nihon Eisai Co Ltd Eisai USA established in 1981 Eisai Inc established in 1995 as US prescription pharmaceutical sales company Research:Eisai Research Institute of Boston, Andover, MA Discovery Research (1987) Process Research and Bulk Production of pharmaceuticals for clinical trials (1994) Eisai Inc, Research Triangle Park NC Pharmaceutical Production and Formulation R&D facility (1997) Eisai Medical Research, Ridgefield, NJ Clinical Research and Clinical Drug Development (2002)

QUICK FACTS PMSIG Prep session 03/01/07 More than 9,000 employees worldwide Eisai Inc had $2.2 billion in sales for 2005 (fiscal year ending March 31, 2006) During the period of 1998 to 2005, Eisai Inc. moved up in the rankings of U.S. pharmaceutical companies from 44 to 19 (based on revenues). Eisai Co shares are traded on the Tokyo Stock Exchange and the Osaka Securities Exchange. American Depository Receipts (ESALY.PK) are available through JPMorgan Chase Last trade: $ week: $ $55.55

PRODUCTS PMSIG Prep session 03/01/07 ARICEPT ® (donepezil hydrochloride) tablets Discovered and developed by Eisai Approved by the FDA in 1996 Treatment of mild to moderate Alzeimer’s disease symptoms. ACIPHEX ® (rabeprazole sodium) tablets Discovered and developed by Eisai Approved by the FDA in 1999 Treatment of acid reflux (proton pump inhibitor) In combination with appropriate antibiotics, approved by the FDA for the eradication of H. Pylori infections, responsible for peptic ulcers. Neurology Gastrointestinal Disorders Oncology / Critical Care

PRODUCTS PMSIG Prep session 03/01/07 CEREBYX ® (phosphenytoin sodium) injectable Acquired exclusive US rights from Pfizer Approved by the FDA in 1996 Used to control general epileptic convulsions and to prevent seizures during brain surgery ZONEGRAN ® (zonisamide) capsules Acquired from Elan in April 2004 Approved by the FDA in 2000 Treatment of epileptic symptoms FRAGMIN ® (dalteparin sodium) injectable Acquired exclusive US rights from Pfizer Clot preventing agent for the prevention of deep vein thrombosis which may lead to pulmonary embolism ®® Neurology Gastrointestinal Disorders Oncology / Critical Care

ALLIANCES PMSIG Prep session 03/01/07 From the start, Eisai pioneered strategic co-promotions or product-focused collaborations to achieve its goal of becoming an integrated pharmaceutical business (R&D, manufacturing, marketing, distribution). PfizerAricept (co-promotion), Cerebyx (exclusive U.S. rights), Fragmin (exclusive U.S. rights) Ortho-McNeilAciphex (co-promotion) ElanZonegran (acquisition) Teva Pharma.Razagiline (co-promotion, co-development) NovartisRufinamide (acquisition)

Eisai Inc. Investing in the Pharmaceutical Industry … Mixing Medicine with Business March 2, :00 am – 8:45 am Breakfast / ”Meet and Greet” with Eisai Management 8:45 am – 9:00 amIntroduction / KickoffMr. Gregory Altamura Human Resources Director, Corporate ER & Recruitment 9:00 am – 9:45 amFinancial Stakeholder PerspectivesMr. Robert Feeney, Director, Investor & Government Relations 9:45 am – 10:30 am Building a BrandMs. Kim Trapani, Associate Director, Zonegran 10:30 am – 10:45 amBreak 10:45 am – 11:30 amGlobal Medical & Marketing Services Mr. Andrew Greene Impacting the Product PortfolioDirector of Marketing, New Products 11:30 am – 12:00 pmOur Value Proposition to all Mr. Frank Ciriello StakeholdersVP, Sales & Marketing 12:00 pm – 12:30 pmQ&A / ClosingAll Presenters 12:30 pm – 1:30 pmLunch / Networking with Eisai Management